Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harriet O Smith

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Applied Optics|April 3, 2009
In vivo light scattering for the detection of cancerous and precancerous lesions of the cervixJudith R Mourant, Tamara M Powers, Thérese J Bocklage, et al.
Gynecologic Oncology|May 26, 2009
Southwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancerHarriet O Smith, James Moon, Sharon P Wilczynski, et al.
Gynecologic Oncology|February 22, 2005
Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology GroupSidney A Scudder, P Y Liu, Sharon P Wilczynski, et al.
Gynecologic Oncology|June 9, 2009
GPR30 predicts poor survival for ovarian cancerHarriet O Smith, Hugo Arias-Pulido, Dennis Y Kuo, et al.
Gynecologic Oncology|February 17, 2007
In vivo light scattering measurements for detection of precancerous conditions of the cervixJudith R Mourant, Thérese J Bocklage, Tamara M Powers, et al.
American Journal of Obstetrics and Gynecology|February 20, 2003
Ethnic differences at risk for gestational trophoblastic disease in New Mexico: A 25-year population-based studyHarriet O Smith, Robert D Hilgers, Edward J Bedrick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 21, 2010
Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancerGloria S Huang, Jurriaan Brouwer-Visser, Marissa J Ramirez, et al.
Gynecologic Oncology|December 8, 2004
Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group studyMace L Rothenberg, P Y Liu, Sharon Wilczynski, et al.
BMC Medical Genomics|December 1, 2020
Utility of a custom designed next generation DNA sequencing gene panel to molecularly classify endometrial cancers according to The Cancer Genome Atlas subgroupsEirwen M Miller, Nicole E Patterson, Gregory M Gressel, et al.
Cancer Cell|April 2, 2019
Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic TargetsLuca Cassetta, Stamatina Fragkogianni, Andrew H Sims, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Applied Optics|April 3, 2009
In vivo light scattering for the detection of cancerous and precancerous lesions of the cervixJudith R Mourant, Tamara M Powers, Thérese J Bocklage, et al.
Gynecologic Oncology|May 26, 2009
Southwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancerHarriet O Smith, James Moon, Sharon P Wilczynski, et al.
Gynecologic Oncology|February 22, 2005
Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology GroupSidney A Scudder, P Y Liu, Sharon P Wilczynski, et al.
Gynecologic Oncology|June 9, 2009
GPR30 predicts poor survival for ovarian cancerHarriet O Smith, Hugo Arias-Pulido, Dennis Y Kuo, et al.
Gynecologic Oncology|February 17, 2007
In vivo light scattering measurements for detection of precancerous conditions of the cervixJudith R Mourant, Thérese J Bocklage, Tamara M Powers, et al.
American Journal of Obstetrics and Gynecology|February 20, 2003
Ethnic differences at risk for gestational trophoblastic disease in New Mexico: A 25-year population-based studyHarriet O Smith, Robert D Hilgers, Edward J Bedrick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 21, 2010
Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancerGloria S Huang, Jurriaan Brouwer-Visser, Marissa J Ramirez, et al.
Gynecologic Oncology|December 8, 2004
Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group studyMace L Rothenberg, P Y Liu, Sharon Wilczynski, et al.
BMC Medical Genomics|December 1, 2020
Utility of a custom designed next generation DNA sequencing gene panel to molecularly classify endometrial cancers according to The Cancer Genome Atlas subgroupsEirwen M Miller, Nicole E Patterson, Gregory M Gressel, et al.
Cancer Cell|April 2, 2019
Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic TargetsLuca Cassetta, Stamatina Fragkogianni, Andrew H Sims, et al.
Pageof 4